166 related articles for article (PubMed ID: 15498602)
21. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease.
Garnett GP
J Infect Dis; 2005 Feb; 191 Suppl 1():S97-106. PubMed ID: 15627236
[TBL] [Abstract][Full Text] [Related]
22. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine.
Harrison CJ; Miller RL; Bernstein DI
Vaccine; 2001 Feb; 19(13-14):1820-6. PubMed ID: 11166907
[TBL] [Abstract][Full Text] [Related]
23. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine.
Jamali A; Mahdavi M; Hassan ZM; Sabahi F; Farsani MJ; Bamdad T; Soleimanjahi H; Motazakker M; Shahabi S
Int Immunol; 2009 Mar; 21(3):217-25. PubMed ID: 19174474
[TBL] [Abstract][Full Text] [Related]
24. Immunostimulatory CpG treatment for genital HSV-2 infections.
Herbst MM; Pyles RB
J Antimicrob Chemother; 2003 Dec; 52(6):887-9. PubMed ID: 14585849
[No Abstract] [Full Text] [Related]
25. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2.
Quenelle DC; Collins DJ; Marciani DJ; Kern ER
Vaccine; 2006 Mar; 24(10):1515-22. PubMed ID: 16288820
[TBL] [Abstract][Full Text] [Related]
26. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
27. Resiquimod 3M.
Jones T
Curr Opin Investig Drugs; 2003 Feb; 4(2):214-8. PubMed ID: 12669385
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial.
Bernstein DI; Wald A; Warren T; Fife K; Tyring S; Lee P; Van Wagoner N; Magaret A; Flechtner JB; Tasker S; Chan J; Morris A; Hetherington S
J Infect Dis; 2017 Mar; 215(6):856-864. PubMed ID: 28329211
[TBL] [Abstract][Full Text] [Related]
29. Treatment of genital herpes infections in HIV-infected patients.
Foley E; Patel R
J HIV Ther; 2004 Feb; 9(1):14-8. PubMed ID: 15071425
[TBL] [Abstract][Full Text] [Related]
30. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant.
Nesburn AB; Ramos TV; Zhu X; Asgarzadeh H; Nguyen V; BenMohamed L
Vaccine; 2005 Jan; 23(7):873-83. PubMed ID: 15603887
[TBL] [Abstract][Full Text] [Related]
31. Susceptibility of human female primary genital epithelial cells to herpes simplex virus, type-2 and the effect of TLR3 ligand and sex hormones on infection.
MacDonald EM; Savoy A; Gillgrass A; Fernandez S; Smieja M; Rosenthal KL; Ashkar AA; Kaushic C
Biol Reprod; 2007 Dec; 77(6):1049-59. PubMed ID: 17881767
[TBL] [Abstract][Full Text] [Related]
32. The Holy Grail: immune control of human herpes simplex virus infection and disease.
Cunningham AL; Mikloska Z
Herpes; 2001 Mar; 8 Suppl 1():6A-10A. PubMed ID: 11867028
[TBL] [Abstract][Full Text] [Related]
33. The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challenges.
Harandi AM
J Clin Virol; 2004 Jul; 30(3):207-10. PubMed ID: 15135735
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.
Bernstein DI; Flechtner JB; McNeil LK; Heineman T; Oliphant T; Tasker S; Wald A; Hetherington S;
Vaccine; 2019 Jun; 37(26):3443-3450. PubMed ID: 31103365
[TBL] [Abstract][Full Text] [Related]
35. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
Pepose JS; Keadle TL; Morrison LA
Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
[TBL] [Abstract][Full Text] [Related]
36. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection.
Bavaro JB; Drolette L; Koelle DM; Almekinder J; Warren T; Tyring S; Wald A
Sex Transm Dis; 2008 Apr; 35(4):383-6. PubMed ID: 18362859
[TBL] [Abstract][Full Text] [Related]
37. Vaccines for herpes simplex virus infections.
Koelle DM
Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine.
Bernstein DI; Aoki FY; Tyring SK; Stanberry LR; St-Pierre C; Shafran SD; Leroux-Roels G; Van Herck K; Bollaerts A; Dubin G;
Clin Infect Dis; 2005 May; 40(9):1271-81. PubMed ID: 15825029
[TBL] [Abstract][Full Text] [Related]
39. NK and NKT cell-independent contribution of interleukin-15 to innate protection against mucosal viral infection.
Gill N; Rosenthal KL; Ashkar AA
J Virol; 2005 Apr; 79(7):4470-8. PubMed ID: 15767447
[TBL] [Abstract][Full Text] [Related]
40. Role of IFN-alpha/beta signaling in the prevention of genital herpes virus type 2 infection.
Svensson A; Bellner L; Magnusson M; Eriksson K
J Reprod Immunol; 2007 Jun; 74(1-2):114-23. PubMed ID: 17092567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
